Natera submitted its Signatera MRD test to Japan’s PMDA as a companion diagnostic for muscle-invasive bladder cancer, supporting disease monitoring alongside Tecentriq in ctDNA-positive patients after cystectomy. The submission relies on data from the double-blind IMvigor011 Phase 3 trial, where Tecentriq nearly doubled disease-free survival versus placebo. Regulatory context matters: the FDA previously approved Signatera for adjuvant Tecentriq, and the NCCN has incorporated MRD-guided adjuvant Tecentriq into bladder cancer guidelines. Japan’s PMDA review also builds on earlier approvals in colorectal cancer. For biotech and diagnostics stakeholders, the filing shows continued expansion of tumor-informed liquid biopsy into geographically distinct regulatory pathways while reinforcing MRD as a decision-driving endpoint in solid tumors.